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The tumour suppressor gene PTEN plays an important somatic role in both hereditary and sporadic breast
carcinogenesis. While the role of PTEN’s lipid phosphatase activity, as a negative regulator of the cyto-
plasmic phosphatidylinositol-3-kinase/Akt pathway is well known, it is now well established that PTEN
exists and functions in the nucleus. Multiple mechanisms of regulating PTEN’s subcellular localization
have been reported. However none are ubiquitous across multiple cancer cell lines and tissue types. We
show here that adenosine triphosphate (ATP) regulates PTEN subcellular localization in a variety of different
cancer cell lines, including those derived from breast, colon and thyroid carcinomas. Cells deﬁcient in ATP
show an increased level of nuclear PTEN protein. This increase in PTEN is reversed when cells are sup-
plemented with ATP, ADP or AMP. In contrast, the addition of the non-hydrolyzable analogue ATPgS, did
not reverse nuclear PTEN protein levels in all the cell types tested. To our knowledge, this is the ﬁrst
report that describes a regulation of PTEN subcellular localization that is not speciﬁc to one cell line or
tissue type, but appears to be common across a variety of cell lineages.
INTRODUCTION
The precise mapping of the Cowden syndrome susceptibility
gene to 10q22-q23 in 1996 facilitated the isolation of phospha-
tase and tensin homologue deleted on chromosome 10 [PTEN
(MIM 601728)], also known as MMAC1 or TEP1, the following
year (1–4). Germline mutations in PTEN have been identiﬁed
in 85% of probands with Cowden syndrome [CS (MIM
158350)], an under-diagnosed autosomal dominant disorder
with a high risk of benign and malignant breast, thyroid and
endometrial neoplasias (5–7). Subsequently, somatic mutations
or deletions of PTEN have been identiﬁed in variable subsets
of a broad range of sporadic tumour types, including those of
the breast, thyroid, colorectum, endometrium, melanoma and
prostate (8–10).
The role of PTEN’s lipid phosphatase activity as a negative
regulator of the cytoplasmic phosphatidylinositol-3-kinase
(PI3K)/Akt pathway is well known. In recent years, we have
begun to elucidate the role of PTEN in regulating cellular path-
ways in other compartments of the cell. Initially we, and others,
had observed PTEN in the nucleus using immunohistochemical
analyses in breast, thyroid, endocrine pancreatic tumours and
cutaneous melanomas (11–13). Subsequent studies, by us, and
others, have shown that PTEN does, indeed, trafﬁc to the
nuclear compartment. Further, PTEN immunohistochemistry
has revealed nuclear expression in several tissue types, including
breast, which appear to be highest in normal cells and diminish,
with concomitant increase in expression in cytoplasm, with neo-
plastic progression, indicating that the subcellular localization
of PTEN plays a role in its function (12,13). Indeed, nuclear
PTEN has been shown to regulate cell cycle and to regulate
MAPK activation (14,15). Nuclear PTEN mediates growth sup-
pression independent of AKT down-regulation and is essential
for maintaining chromosomal integrity through physical associ-
ation with the kinetochore (16).
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motifs on PTEN (17–19), recent studies have shown that
several mechanisms appear to modulate its localization. These
include a cytoplasmic localization signal (CLS) (20), PTEN
phosphorylation and involvement of Ran-GTPase activity
(21,22), interaction with Major Vault Protein (MVP) via a
bipartite NLS (17,23), mono-ubiquitination (18), S6K-mediated
export (24) and passive diffusion (25). Despite this diverse
range of mechanisms, none of the current modes of regulation
appear to be universally applicable across a variety of cell
lines or tissue/tumour types.
The modulation of adenosine triphosphate (ATP) levels has
been shown to be therapeutically relevant in the cancer ﬁeld
(26). ATP depletion, when used in combination with che-
motherapy and/or radiation, has a variety of effects on cancer
cells including inducing apoptosis in multi-drug resistant cells
and decreasing tumour promotion (26–31). The exact mechan-
isms of these effects have not been fully elucidated. Interest-
ingly, several have shown that the PI3K/Akt, pathways also
modulated by PTEN, may play a role in these effects (32,33).
Active transport, of molecules and proteins, has been demon-
strated in a variety of systems (34–37). Interestingly, despite
this evidence, there has been no examination of the potential
role of ATP in modulating PTEN’s subcellular localization.
Based on other protein requirements for active transport, we
hypothesized that PTEN would require ATP for its nuclear-
cytoplasmic shuttling. Therefore, we sought to examine the
effects of ATP modulation on intracellular PTEN localization.
RESULTS
Cellular ATP depletion increases nuclear PTEN in breast,
colorectal and thyroid carcinoma cells
In order to examine the requirements of ATP for PTEN sub-
cellular localization, we ﬁrst established a system in which
we could deplete cellular ATP levels in a reversible manner.
Towards this end, we utilized the conventional method of
2-deoxy-D-glucose (2-DG) and sodium azide (35,37). Treat-
ment using glucose-free media containing 2-DG and sodium
azide (ATP depletion media) reduced total cellular ATP
levels by 90% in 4 h, compared with untreated control cells
(Fig. 1). ATP levels could be restored, in a time-dependent
manner, by the removal of the ATP depletion media containing
the metabolic inhibitors and the addition of fresh glucose-free
medium (regeneration media) to each cell line. Within 4 h,
cellular ATP levels had been restored to 61% of that observed
in control cells (Fig. 1). Results comparable to those in Figure 1
were obtained, with each of the other cell lines used in this
study, in terms of both the magnitude and time-course of
ATP depletion and regeneration (data not shown). In this
system, we observed, as expected, decreased phosphorylation
of MAPK, Akt and PTEN in the ATP depleted state (data not
shown). As expected, these molecules were re-phosphorylated
when ATP levels were restored.
Having established a system in which we could reproducibly
modulate ATP levels, we next examined the effect of cellular
ATP depletion on PTEN subcellular localization. In untreated
breast cancer lines, PTEN is present in both the nuclear and
cytosolic fractions with MDA-MB-231 breast cancer cells
having a higher basal level of nuclear PTEN levels than
MCF7 breast cancer cells (Fig. 2A and B). After ATP depletion,
total intracellular ATP levels in all cell lines studied decreased
to 8–12% of control non-treated cells. In breast cancer lines,
ATP depletion resulted in an increase in nuclear PTEN levels,
in a time-dependent manner, peaking at 3–4 h (Fig. 2A and
B). This was not simply due to an increase in cytosolic contami-
nation, as a-tubulin protein was not detected in the nuclear frac-
tions. In the lines tested, we did not observe a concomitant
decrease in cytoplasmic PTEN. This is not unexpected as the
vast majority of PTEN is localized in the cytoplasm with a
small, but distinct portion present in the nucleus (Fig. 2A–D).
The relatively small cytosolic decrease is difﬁcult to detect by
western blot. Nevertheless, our data shows that following
ATP depletion, the level of PTEN present in the nucleus
increases, resulting in a large relative change (Fig. 2A–D).
Because previous work has suggested that mechanisms of
PTEN subcellular localization may be cell line-dependent
(19), we examined the effect of cellular ATP depletion in
both colon and thyroid cancer cell lines. Similar to what was
observed in the breast cancer cell lines, there was a basal
level of nuclear PTEN prior to ATP depletion in both colon
(Fig. 2C, Supplementary Material, Fig. S1) and thyroid
(Fig. 2D) lines. Additionally, as was observed in the breast
cancer lines, depletion of cellular ATP in each of the colon
and thyroid cancer cell lines resulted in a time-dependent
increase of nuclear PTEN protein (Fig. 2C and D, Supplemen-
tary Material, Fig. S1). The data presented in Figure 2 demon-
strate that the depletion of ATP for 4 h results in a
reproducible increase of nuclear PTEN in carcinoma cell
lines derived from three different origins.
In order to corroborate the biochemical analyses presented
above, we used indirect-immunoﬂuorescence to examine the
changes in subcellular localization of endogenous PTEN, fol-
lowing ATP depletion in breast, colon and thyroid carcinoma
cells (Fig. 3, Supplementary Material, Fig. S2B and C). In
agreement with the biochemical observations above, PTEN
is found in both the cytoplasm and nucleus in untreated cells
of all cell types (complete medium; Fig. 3A–D). After cellular
ATP depletion, a gradual increase in nuclear PTEN levels was
observed, which peaked at 4 h in all cell lines (ATP depletion,
2, 3 and 4 h; Fig. 3A–D). Merging of the nuclear (DAPI) and
PTEN (FITC) images conﬁrmed that the localization of PTEN
became more nuclear following ATP depletion for 3–4 h
(Fig. 3A and B, panels i, l, o; Fig. 3C panels f, i, l; Fig. 3D,
panels f, i, l). Incubation of cells in glucose-free medium did
not alter the localization of PTEN (Fig. 3A, panels b versus
e), demonstrating that the localization changes were due to
an active depletion of ATP and not simply a withdrawal of
glucose from the system.
Regeneration of cellular ATP decreased nuclear
PTEN to basal levels
To determine if increased nuclear PTEN localization resulting
from cellular ATP depletion was reversible, we depleted ATP
in the cells, as previously described. We then removed the
ATP depletion media containing the metabolic inhibitors
and added fresh glucose-free medium (regeneration media)
to each cell line, allowing the regeneration to continue, in a
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h a db e e nr e s t o r e dt o61% of that observed in control cells
(Fig. 1). When we examined the levels of nuclear PTEN follow-
ing ATP regeneration, by both western analysis (Fig. 2A–D)
and immunoﬂuorescence (Fig. 3A and B), we found that in
each case, nuclear PTEN levels were lower in the cells in
which ATP was allowed to regenerate compared with nuclear
PTEN levels observed in ATP-depleted cells (Fig. 3). This con-
ﬁrmed that, in all three cell types (regeneration immunoﬂuoros-
cence data only shown for MCF7 cells), nuclear PTEN levels
increased in the absence of ATP, while nuclear PTEN decreased
in response to increasing ATP levels.
Metabolites of ATP, but not ATPgS can modulate PTEN
localization
Based on our results, we chose to examine whether metabolites
of ATP are able to reverse the nuclear localization observed
in cellular ATP-depleted cells. To this end, following ATP
depletion, we supplemented the glucose-free regeneration
media with ATP, ADP, AMP, deoxy-ATP (dATP) or the non-
hydrolyzable ATP analogue, ATPgS. The addition of each
component to the regeneration media affected the regenerated
levels of cellular ATP. In adenosine nucleoside- and glucose-
free regeneration media, the cellular ATP levels were 61%
of the ATP levels measured in control cells. The addition
of ATP to the regeneration media resulted in cellular ATP
levels that were 76% of control cells. The addition of other
components also inﬂuenced ATP regeneration, with the addition
of ADP resulting in regeneration of ATP to 71% of control, of
AMP 66% of control, of ATPgS 12% of control levels and
of dATP 54% of control levels (data not shown).
As shown above, nuclear PTEN increased when cellular
ATP was depleted in breast, thyroid and colon cancer lines
(Figs 2 and 3, Supplementary Material, Fig. S1 and S2). We
found that the addition of ATP, ADP or AMP resulted in a
decrease in nuclear PTEN protein across breast, colon and
thyroid cancer cells lines (Fig. 4, Supplementary Material,
Fig. S3). In contrast, the addition of ATPgS did not reverse
the ATP-dependant change in nuclear PTEN levels in any
of the cell lines (Fig. 4A–D). Interestingly, supplementation
with dATP, after cellular ATP depletion, reversed PTEN
nuclear localization only in colon cells. In breast and thyroid
cancer cells, this effect was subtle.
DISCUSSION
While there is now increasing evidence of the role of proper
intracellular localization in the regulation of PTEN’s function,
the mechanism of PTEN nuclear transport is not clear (19).
PTEN does not possess a traditional NLS. Several mechanisms
have been proposed for localization of PTEN to the nucleus;
however, to date, a common mechanism has not been eluci-
dated (14,17–25). Interestingly, active transport and the role
of ATP has not been previously investigated. Based upon
other proteins’ requirement for active transport (34–37), we
Figure 1. Depletion and regeneration of cellular ATP depletion in cultured cancer cells. For cellular depletion of ATP, cells were incubated in glucose-free media
containing 6 mM 2-deoxy-D-glucose and 10 mM sodium azide. ATP levels were measured using the luciferase–luciferin method, as described in the Materials
and Methods. Note that ATP depletion effectively reduced total cellular ATP levels by 90% in 4 h, compared with untreated control cells. ATP levels could be
restored by the removal of the ATP depletion media, containing the metabolic inhibitors, and the addition of fresh glucose-free medium (regeneration media).
This representative graph shows ATP levels in the MCF-7 breast cell line.
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import. Surprisingly, we found that depletion of cellular
ATP resulted in increased nuclear PTEN levels in a variety
of cancer cell types.
Our current observations suggest that nuclear PTEN
accumulation requires ATP for either active export from the
nucleus or that there is a loss of ATP-dependent inhibition
of nuclear import. This effect on PTEN localization was
reversible as regeneration of ATP, either through replacement
of the media or through supplementation, resulted in a
decrease in nuclear PTEN levels. Addition of ATP to the
regeneration media increased the total intracellular ATP
levels as well as reversed the increase in nuclear PTEN
observed following ATP depletion. That the ATP-related
nucleotides ADP, AMP, and to a much lesser extent dATP,
also facilitated these changes suggests that the cells remained
capable of producing ATP throughout the depletion process.
Supplementation with ATP precursors enhanced the regener-
ation process, and as a result, both increased ATP levels and
decreased nuclear PTEN. In contrast, addition of ATPgSt o
the ATP regeneration media did not result in an enhanced
recovery of ATP levels or a decrease in nuclear PTEN. This
difference highlights that it is the functional aspects of ATP
and/or its related compounds that are important factors in
PTEN’s localization, not simply the structural aspects of
ATP in general.
Our results with ATPgS also suggest that protein phos-
phorylation may play a role in the subcellular localization of
PTEN. Direct phosphorylation has been suggested to play a
role in PTEN function. Indeed, phosphorylation of PTEN
plays a role in its stability and others have demonstrated
that phosphorylated PTEN can modulate its location in
speciﬁc cell types (21,22). However, we have shown that
in MCF7 cells, PTEN nuclear localization is independent of
PTEN phosphorylation (17). This system provides further
evidence that nuclear import of PTEN is independent of its
Figure 2. Depletion of cellular ATP increases nuclear PTEN protein levels in a reversible manner. Cells were grown and maintained as described in the Materials
and Methods. Control cells were maintained in complete medium or glucose-free medium. Cellular ATP was depleted using ATP-depletion media for up to 4 h.
Where indicated, ATP was regenerated for 2–4 h. At the indicated time-points, control, ATP-depleted and regenerated cells were subjected to subcellular frac-
tionation and analyzed by western blot for PTEN, a-tubulin (cytosolic marker) or PARP-1 (nuclear marker). (A) MCF7 and (B) MDA-MB-231 breast carcinoma
cell lines, (C) RKO colorectal carcinoma cell line and (D) WRO-82-1 follicular thyroid cell line.
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(where nuclear PTEN increases) PTEN is not phosphorylated
(Supplementary Material, Fig. S4). However, it remains a
possibility that the phosphorylation of another key protein is
important for either inhibiting ATP import or in facilitating
PTEN export. An example of phosphorylation-dependent
export is the DNA-PK-dependent nuclear export of androgen
receptor, which has been demonstrated in prostate cancer
cells (38). In this system, DNA-PK phosphorylates the andro-
gen receptor or an interacting component, resulting in nuclear
export. While we do not postulate that DNA-PK is involved in
our system, this system demonstrates the possibility of this
Figure 3. Depletion of cellular ATP increases nuclear PTEN protein levels in a reversible manner. Cells were grown and maintained for microscopy studies as
described in the Methods. Cells were depleted of cellular ATP using ATP depletion media for 4 h. If indicated, ATP was regenerated for 2–4 h. At the indicated
times, cells were ﬁxed using 4% paraformaldehyde and processed for indirect immunoﬂuorescence as described. PTEN localization was determined utilizing a
FITC-conjugated anti-mouse secondary antibody and nuclei were stained using DAPI. Representative data are shown for (A and B) MCF-7 breast carcinoma
cells, (C) RKO colorectal carcinoma cells and (D) WRO-82-1 follicular thyroid carcinoma cells. The other cell lines studied had similar responses and are shown
in the supplemental data. All experiments were carried out in duplicate. Approximately 200 cells were counted per individual time point and representative
images from three separate experiments are shown. All images were acquired at  20 magniﬁcation.
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involves the Ran-GDP/Ran-GTP model. Yoneda and col-
leagues isolated an ATP-dependent activity that stimulated
the release of GDP from Ran in the presence of NTF2 (39).
GDP release allowed for an association between Ran and
GTP that facilitates exportin-mediated nuclear export. ATP
enhanced the GDP release and this enhancement was inhibited
by non-hydrolysable ATP analogues. In addition, the inhi-
bition of protein phosphatase activity enhanced this activity,
suggesting that it may be regulated by a phosphorylation
Figure 4. Metabolites of ATP, but not ATPgS, decreased nuclear PTEN levels. Cells were ATP-depleted for 2 h using ATP-depletion media, after which the
depletion medium was replaced with glucose-free medium supplemented with 2 mM of either ATP, ADP, dATP, AMP, or ATPgS. Cells were subjected to sub-
cellular fractionation and western analysis. Representative autoradiographs are from the analyses of (A) MCF7 breast carcinoma cells, (B) RKO colorectal car-
cinoma cells and (C) WRO-82-1 thyroid carcinoma cells. The remaining breast and colorectal cell lines behaved similarly and their data can be viewed in the
supplemental data ﬁle. (D) To determine the effects on these tested cell lines, we quantitated the relative amount of nuclear PTEN protein by densitometry to
obtain the ratio of nuclear PTEN to the nuclear loading control PARP-1. This ratio of nuclear-PTEN to PARP-1 was normalized to 1.0 in untreated cells (left-
most 3 bars). Each bar depicts the mean+SEM of three individual experiments.
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that we observe, as the Ran-mediated mechanism of nuclear
PTEN import does not appear to be involved in PTEN
nuclear import in MCF7 cells (Minaguchi and Eng, unpublished
results); however, this does not preclude a similar mechanism
from being involved. It is also worthy to note that we have
not seen a change in nuclear PTEN protein levels in MCF7
cells treated with the Protein Kinase C inhibitors staurosporin
or GF10923X (Minaguchi and Eng, unpublished results).
These results may suggest that PKC-dependent protein phos-
p h o r y l a t i o nm a yn o tb ei n v o l v e di nt h ec o m m o nm e c h a n i s m
that we are observing here; however, further studies into this
potential mechanism, while beyond the scope of this paper,
may be fruitful.
Nuclear PTEN has been shown to be involved in several
cellular processes such as cell cycle regulation, down-regulation
of the MAPK signalling cascade and increases in apoptosis.
Determination of the downstream effects of the ATP depletion-
dependent increase in nuclear PTEN is problematic in our model
system. The nearly complete depletion of cellular ATP renders
examination of protein activation in the MAPK cascade by
phosphorylation status uninterpretable, as all proteins become
hypo-phosphorylated (including PTEN itself) under these experi-
mental conditions. Additionally, following incubation under
ATP-depleting conditions for .5 h , most cells were found to
detach from the tissue culture plates, rendering cell cycle analysis
difﬁcult. These issues were not surprising considering the import-
ance of ATP in cellular homeostasis. Nonetheless, we found that
following 3–4 h under ATP depletion, MDA-MB-231, MCF-7
and RKO cells all demonstrated a slight increase in TUNEL and
Annexin V staining (data not shown). The MDA-MB-231 cells
demonstrated a 2-fold higher level of TUNEL staining than the
MCF-7 and RKO cells. Interestingly, it was the MDA-MB-231
cells that also demonstrated the greatest increase in nuclear
PTEN in response to ATP depletion, suggesting that this
apoptotic response might indeed be a result of the increase
in nuclear PTEN. While these results were preliminary, they
highlight the need for future investigations into the role of ATP
in modulating nuclear PTEN levels.
That manipulation of ATP levels in the cell results in nuclear
localization of PTEN may suggest the involvement of intra-
cellular energy-sensing mechanisms. This is an interesting
area that warrants further investigation, particularly in light of
potential cancer therapies that could manipulate energy and
therefore regulate the localization of PTEN. Recently, work
by Liu et al. have demonstrated in glioblastoma, that TSC2
and S6Kinase 1/2 activation are involved in the export of
PTEN from the nucleus (24). Further elucidation of components
of this potential signalling pathway leading to PTEN export,
while beyond the scope of this paper, would be recommended.
We present here the ﬁrst evidence of a common regulation
of PTEN localization that is present not only in a few cell
lines derived from speciﬁc tissues but a variety of cell types,
including breast, colon and thyroid lines. Our observations
have broad implications, from carcinoma progression, invasion
and metastases to therapy. For example, energy levels must
vary with the development and progression of carcinomas and is
absolutely tied to hypoxia (40). Furthermore, our data may also
suggest that the manipulation of cellular energy levels could be
an important target for cancer therapy that may have an effect
onavarietyofcancers.ThatdepletionofATPresultsinanincrease
in nuclear PTEN, in a variety of cell lines from diverse lineages,
suggests that altering the subcellular localization of PTEN
through modulation of ATP levels may be a beneﬁcial adjunct
to traditional therapies in multiple tumour types.
In fact, modulation of ATP levels has been shown to be thera-
peutically relevant. Maschek and colleagues demonstrated that
treatment with 2-DG signiﬁcantly enhances the effectiveness
of paclitaxel and adriamycin in a xenograft model of human
osteosarcoma and non-small cell lung carcinoma (27). It may
be important to note that clinical treatments that result in ATP
depletion, when used in combination with radiation or che-
motherapeutic treatment, appears to result in enhanced tumour
regression in a variety of preclinical studies (26–31). These pre-
clinical and clinical studies show that ATP depletion may be a
well-tolerated adjunctive therapy to traditional chemotherapeutic
and radiotherapy regimens. It is intriguing to speculate that the
underlying cause of this increase in efﬁcacy might be due to the
ATP depletion-mediated increases in nuclear PTEN levels. This
both afﬁrms the potential utility of agents that increase nuclear
PTEN levels in the development of future combinatorial thera-
pies and demonstrates the need for an increased understanding
of the mechanisms of nucleo-cytoplasmic shuttling of PTEN in
both sporadic malignancies as well as neoplasias relevant to
Cowden syndrome for treatment and prevention.
MATERIALS AND METHODS
Materials
Glucose-free DMEM and RPMI were from GIBCO BRL
(Hercules, CA). ATP Bioluminescence Assay Kit CLS II was
from Roche Applied Sciences (Indianapolis, IN). Prolong Gold
antifade mounting medium was purchased from Invitrogen
(Carlsbad, CA). NE-PER kit and BCA protein assay kit were
from Pierce Biotechnology Inc. (Rockford, IL). Antibodies
used were a-PTEN monoclonal antibody clone 6H2.1 (Cascade
Biosciences, Portland, OR), phospho-PTEN, a-tubulin and
a-PARP-1 antibody (Cell Signaling Technologies, Danvers,
MA). All other chemicals/reagents were obtained from common
commercial sources.
Cell lines and culture conditions
MCF7, MDA-MB-231, breast carcinoma lines and WRO-82-1
follicular thyroid carcinoma lines were maintained in high-
glucose DMEM supplemented with 10% fetal bovine serum
(FBS), 1% penicillin–streptomycin sulphate. HT29, GC3 and
RKO colorectal cell lines were maintained in high-glucose
RPMI supplemented with 10% FBS, 1% penicillin–streptomycin
sulphate. All cell lines were maintained at 378Ca n d5 %C o 2.
All cell lines were screened for PTEN mutations in the coding,
ﬂanking intronic and minimal promoter regions using both
DGGE and automated sequencing. All cell lines studied express
wild-type PTEN.
Cellular ATP depletion
Cells were seeded at a density of 2   10
6 per 100 mm dish in
complete medium and allowed to adhere overnight. Control
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glucose-free medium. For ATP depletion, cells were incubated
in glucose-free media (Gluc-medium) containing 10 mM
sodium azide and 6 mM 2-DG, supplemented with 10% FBS
and 1% penicillin–streptomycin sulphate, at the times indicated
(35,37). Intracellular ATP levels were determined using a biolu-
minescent luciferase–luciferin somatic cell assay kit according
to the manufacture’s instructions (Roche Applied Sciences,
Indianapolis, IN). Brieﬂy, at the time of harvesting, one-third
of the cells were collected and processed for recovery of free
ATP. Following ATP depletion, the cells undergo morpho-
logical changes, similar to those described by others (35,37).
While this varies across cell lines, in general, we found that at
2 h post-ATP depletion the cells begin to round up and that
by 5 h post-depletion they are beginning to detach from the
culture dish. Based on these observations, we chose the 4 h post-
depletion time for analysis.
Regeneration of cellular ATP
After cellular ATP depletion, as described above, the media
was replaced with fresh glucose-free medium supplemented
with 10% FBS and 1% penicillin–streptomycin sulphate. In
some experiments, as indicated in ﬁgures and ﬁgure legends,
the ATP-regeneration media was supplemented with 2 mM
of either ATP, dATP, ADP, AMP or ATPgS, Regeneration
was carried out for a maximum of 4 h as indicated in ﬁgures
and ﬁgure legends. Intracellular ATP levels, post-regeneration,
were determined as described above.
Subcellular isolation and western blot analysis
Nuclear and cytoplasmic proteins were isolated as previously
described (14,23) using the NE-PER nuclear-cytoplasmic
extraction reagents according to the manufacturer’s instruc-
tions (Pierce, Rockford, IL). Proteasome and phosphatase
inhibitors were added to the extractions buffers at the follow-
ing concentrations: 0.5 mg/ml bezamidine hydrochloride;
2 mg/ml each of leupeptin, aprotinin and pepstatin A; 10 mM
b-glycerophosphate; 0.2 mM sodium orthovanadate; 2 mM
phenylmethylsulfonyl ﬂuoride and 25 mM sodium ﬂuoride.
Protein concentrations were determined using the BCA
assay, using BSA as a standard. Proteins were separated on
10% SDS–PAGE gels using the Criterion system (Bio-Rad,
Hercules, CA) and transferred to nitrocellulose. Equal
protein loading was conﬁrmed by staining the nitrocellulose
blots with Ponceau S and by western analysis with a-tubulin
(cytosolic protein) or a-PARP-1 (nuclear protein). Blots
were probed with either, a-PTEN, a-tubulin or a-PARP-1,
at 1:1000 dilution, then incubated with the appropriate
secondary antibody as previously described (14,23). Proteins
were visualized using enhanced chemiluminescence.
Indirect immunoﬂuoroscence
Cells were prepared for indirect immunoﬂuoroscence as pre-
viously described (14) with minor modiﬁcations. Cells were
grown on coverslips in 6-well dishes in tandem with cells
for nuclear-cytoplasmic protein extracts. Cells were ﬁxed in
freshly prepared 4% paraformaldehyde for 20 min, blocked
using blocking solution (2% BSA and 0.2% Triton-X 100 in
PBS) for 10 min and immunostained with a-PTEN antibody
(1:100) for 1 h at room temperature. Cells were subsequently
washed with PBS and incubated with an a-mouse FITC-
conjugated secondary antibody (1:100) for 1 h at room temp-
erature. After washing with PBS, coverslips were mounted
face down on glass slides (Labtek Inc., Grand Rapids, MI)
with a small drop of mounting medium, ProLong Gold
antifade containing DAPI. Cells were viewed with a Zeiss
Axio ﬂuorescent microscope (Imager A1) (Carl Zeiss Inc.,
Thornwood, NY) with an Achroplan 20  and 40  objective
that had a numerical aperture of 0.50, ﬁtted with ﬁlters for
FITC and DAPI identiﬁcation and equipped with a computer-
supported imaging system. Images were captured using Zeiss’
AxioCam MRc5 high-resolution digital camera in conjunction
with the AxioVision 4.5 multi-channel ﬂuorescent acquisition
software. Background correction settings with the computer
support were standardized for all images. Approximately
200 cells, from 15–20 ﬁelds, were counted per slide.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
The authors thank Drs Bin Zhang, Josephine Adams and Jun
Peng and Ms. Banu Gopalan for helpful discussions. We also
thank Jennifer DeVecchio and Cathy Shemo for assistance
with the Annexin V staining and TUNEL assay, and Frank
Mularo for screening the cell lines for PTEN mutations. C.E.
is an Honorary Fellow of the Cancer Research UK Human
Cancer Genetics Research Group, University of Cambridge, UK.
Conﬂict of Interest statement. None declared.
FUNDING
This work was funded, in part, by the National Cancer
Institute, Bethesda, MD (1R01CA118980-01A2 to C.E.) and
the William Randolph Hearst Foundation (to C.E.). C.E. is a
recipient of the Doris Duke Distinguished Clinical Scientist
Award and holds the Sondra J. & Stephen R. Hardis Chair
in Cancer Genomic Medicine at the Cleveland Clinic.
Funding to pay the Open Access publication charges for this
article was provided by National Institutes of Health grant
number NIH 1RO1CA118980-01A2.
REFERENCES
1. Nelen, M.R., Padberg, G.W., Peeters, E.A., Lin, A.Y., van den Helm, B.,
Frants, R.R., Coulon, V., Goldstein, A.M., van Reen, M.M., Easton, D.F.
et al. (1996) Localization of the gene for Cowdens disease to chromosome
10q22–23. Nat. Genet., 13, 114–116.
2. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J.,
Miliaresis, C., Rodgers, L., McCombie, R. et al. (1997) PTEN, a putative
protein tyrosine phosphatase gene mutated in human brain, breast, and
prostate cancer. Science, 275, 1943–1947.
3. Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon,
A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T. et al. (1997)
Identiﬁcation of a candidate tumour suppressor gene, MMAC1, at
2884 Human Molecular Genetics, 2008, Vol. 17, No. 18chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat. Genet., 15, 356–362.
4. Li, D.M. and Sun, H. (1997) TEP1, encoded by a candidate tumor
suppressor locus, is a novel protein tyrosine phosphatase regulated by
transforming growth factor beta. Cancer Res., 57, 2124–2129.
5. Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S.,
Call, K.M., Tsou, H.C., Peacocke, M. et al. (1997) Germline mutations
of the PTEN gene in Cowden’s disease: an inherited breast and thyroid
cancer syndrome. Nat. Genet., 16, 64–67.
6. Marsh, D.J., Coulon, V., Lunetta, K.L., Rocca-Serra, P., Dahia, P.L.,
Zheng, Z., Liaw, D., Caron, S., Duboue, B., Lin, A.Y. et al. Mutation
spectrum and genotype analyses in Cowden disease and
Bannayan-Zonana syndrome, two hamartoma syndromes with germline
PTEN mutation. Hum. Mol. Genet., 7, 507–515.
7. Zhou, X.P., Waite, K.A., Pilarski, R., Hampel, H., Fernandez, M.J., Bos,
C., Dasouki, M., Feldman, G.L., Greenberg, L.A., Ivanovich, J. et al.
Germline PTEN promoter mutations and deletions in Cowdens/
Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein
and dysfunction of the phosphoinositol-3-kinase/Akt pathway.
Am. J. Hum. Genet., 73, 404–411.
8. Eng, C. (2003) PTEN: one gene, many syndromes. Hum. Mutat., 22,
183–198.
9. Zbuk, K. and Eng, C. (2007) Cancer phenomics: RET and PTEN and
illustrative models. Nat. Rev. Cancer, 7, 35–45.
10. Nassif, N.T., Lobo, G.P., Wu, X., Henderson, C.J., Morrison, C.D., Eng,
C. and Segalov, E. (2004) PTEN mutations are common in sporadic
microsatellite stable colorectal cancer. Oncogene, 23, 617–628.
11. Whang, Y.E., Wu, X., Suzuki, H., Reiter, R.E., Tran, C., Vessella, R.L.,
Said, J.W., Isaacs, W.B. and Sawyers, C.L. (1998) Inactivation of the
tumor suppressor PTEN/MMAC1 in advanced human prostate cancer
through loss of expression. Proc. Natl. Acad. Sci. USA, 95, 5246–5250.
12. Perren, A., Weng, L.P., Boag, A.H., Ziebold, U., Thakore, K., Dahia, P.L.,
Komminoth, P., Lees, J.A., Mulligan, L.M., Mutter, G.L. and Eng, C.
(1999) Immunohistochemical evidence of loss of PTEN expression in
primary ductal adenocarcinomas of the breast. Am. J. Pathol., 155,
1253–1260.
13. Gimm, O., Perren, A., Weng, L.P., Marsh, D.J., Yeh, J.J., Ziebold, U., Gil,
E., Hinze, R., Delbridge, L., Lees, J.A. et al. (2000) Differential nuclear
and cytoplasmic expression of PTEN in normal thyroid tissue, and benign
and malignant epithelial thyroid tumors. Am. J. Pathol., 156, 1693–1700.
14. Chung, J.H. and Eng, C. (2005) Nuclear-cytoplasmic partitioning of
phosphatase and tensin homologue deleted on chromosome 10 (PTEN)
differentially regulates the cell cycle and apoptosis. Cancer Res., 65,
8096–8100.
15. Ginn-Pease, M.E. and Eng, C. (2003) Increased nuclear phosphatase and
tensin homologue deleted on chromosome 10 is associated with G0-G1 in
MCF-7 cells. Cancer Res., 63, 282–286.
16. Shen, W.H., Balajee, A.S., Wang, J., Wu, H., Eng, C., Pandolﬁ, P.P. and
Yin, Y. (2007) Essential role for nuclear PTEN in maintaining
chromosomal integrity. Cell, 128, 157–170.
17. Chung, J.H., Ginn-Pease, M.E. and Eng, C. (2005) Phosphatase and tensin
homologue deleted on chromosome 10 (PTEN) has nuclear localization
signal-like sequences for nuclear import mediated by major vault protein.
Cancer Res., 65, 4108–4116.
18. Trotman, L.C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J.,
Yang, H., Pavletich, N.P., Carver, B.S., Cordon-Cardo, C.,
Erdjumenr-Bromage, H. et al. (2007) Ubiquitination regulates PTEN
nuclear import and tumor suppression. Cell, 128, 141–156.
19. Planchon, S.M., Waite, K.W. and Eng, C. (2007) The nuclear affairs of
PTEN. J. Cell Sci., 121, 249–253.
20. Denning, G., Jean-Joseph, B., Prince, C., Durden, D.L. and Vogt, P.K.
(2007) A short N-terminal sequence of PTEN controls cytoplasmic
localization and is required for suppression of cell growth. Oncogene,
26, 3930–3940.
21. Liu, J.L., Sheng, X., Hortobagyi, Z.K., Mao, Z., Gallick, G.E. and Yung,
W.K. (2005) Nuclear PTEN-mediated growth suppression is independent
of Akt down-regulation. Mol. Cell. Biol., 25, 6211–6224.
22. Gil, A., Andres-Pons, A., Fernandez, E., Valiente, M., Torres, J., Cervera,
J. and Pulido, R. (2006) Nuclear localization of PTEN by a Ran-dependent
mechanism enhances apoptosis: involvement of an N-terminal nuclear
localization domain and multiple nuclear exclusion motifs. Mol. Biol.
Cell, 17, 4002–4013.
23. Minaguchi, T., Waite, K.A. and Eng, C. (2006) Nuclear localization of
PTEN is regulated by Ca(2þ) through a tyrosil
phosphorylation-independent conformational modiﬁcation in major vault
protein. Cancer Res., 66, 11677–11682.
24. Liu, J.L., Mao, Z., LaFortune, T.A., Alonso, M.M., Gallick, G.E.,
Fueyo, J. and Yung, W.K. (2007) Cell cycle-dependent nuclear export
of phosphatase and tensin homologue tumor suppressor is regulated
by the phosphoinositide-3-kinase signaling cascade. Cancer Res., 67,
11054–11063.
25. Liu, F., Wagner, S., Campbell, R.B., Nickerson, J.A., Schiffer, C.A. and
Ross, A.H. (2005) PTEN enters the nucleus by diffusion. J. Cell Biochem.,
96, 221–234.
26. Pelicano, H., Martin, D.S., Xu, R.-H. and Huang, H. (2006) Glycolysis
inhibition for anticancer treatment. Oncogene, 25, 4633–4646.
27. Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K.,
Tidmarsh, G.F., De Young, L.R. and Lampidis, T.J. (2004)
2-deoxy-D-glucose increases the efﬁcacy of adriamycin and paclitaxel in
human osteosarcoma and non-small cell lung cancers in vivo. Cancer
Res., 64, 31–34.
28. Martin, D.S., Bertino, J.R. and Koutcher, J.A. (2000) ATP
depletionþpyrimidine depletion can markedly enhance cancer therapy:
fresh insight for a new approach. Cancer Res., 60, 6776–6783.
29. Zhang, X.D., Deslandes, E., Villedieu, M., Poulain, L., Duval, M.,
Gauduchon, P., Schwartz, L. and Icard, P. (2006) Effect of
2-deoxy-D-glucose on various malignant cells in vitro. Anticancer Res.,
26, 3561–3566.
30. Zhu, Z., Jiang, W., McGinley, J.N. and Thompson, H.J. (2005)
2-Deoxyglucose as an energy restriction mimetic agent: effects on
mammary carcinogenesis and on mammary tumor cell growth in vitro.
Cancer Res., 65, 7023–7030.
31. Aft, R.L., Lewis, J.S., Zhang, F., Kim, J. and Welch, M.J. (2003)
Enhancing targeted radiotherapy by
copper(II)diacetyl-bis(N4-methylthiosemicarbazone) using
2-deoxy-D-glucose. Cancer Res., 63, 5496–5504.
32. Elstrom, R.L., Bauer, D.E., Buzzai, M., Karnauskas, R., Harris, M.H.,
Plas, D.R., Zhuang, H., Cinalli, R.M., Alavi, A., Rudin, C.M. et al.
(2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res.,
64, 3892–3899.
33. Karnauskas, R., Niu, Q., Talapatra, S., Plas, D.R., Grenne, M.E., Crispino,
J.D. and Rudin, C.M. (2003) Bcl-x(L) and Akt cooperate to promote
leukomogenesis in vivo. Oncogene, 22, 688–689.
34. Kose, S., Imamoto, N. and Yoneda, Y. (1999) Distinct energy requirement
for nuclear import and export of importin b in living cells. FEBS Lett.,
463, 327–330.
35. Schwoebel, E.D., Ho, T.H. and Moore, M.S. (2002) The mechanism of
inhibition of Ran-dependent nuclear transport by cellular ATP depletion.
J. Cell Biol., 157, 963–974.
36. Hetzer, M. and Mattaj, I.W. (2000) An ATP-dependent, Ran-independent
mechanism for nuclear import of the U1A and U2B” splicesome proteins.
J. Cell Biol., 2, 293–303.
37. Jeyaraj, S.C., Dakhlallah, D., Hill, S.R. and Lee, B.S. (2006) Expression
and distribution of HuR during ATP depletion and recovery in proximal
tubule cells. Am. J. Physiol. Renal Physiol., 291, F1255–F1263.
38. Shank, L.C., Kelly, J.B., Gioeli, D., Yang, C.S., Spencer, A., Allison, L.A.
and Paschal, B.M. (2008) Activation of the DNA-dependent protein
kinase stimulates nuclear export of the androgen receptor in vitro. J. Biol.
Chem., 283, 10568–10580.
39. Yamada, M., Mattaj, I.W. and Yoneda, Y. (2004) An ATP-dependent
activity that releases RanGDP from NTF2. J. Biol. Chem., 279,
36228–36234.
40. Taylor, C.T. (2008) Mitochondria and cellular oxygen sensing and the
HIF pathway. Biochem. J., 409, 19–26.
Human Molecular Genetics, 2008, Vol. 17, No. 18 2885